| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 141 | Inflammation, autoimmune disease, the binding material for allergic disease treatment | JP51364296 | 1995-10-20 | JPH10507460A | 1998-07-21 | ー イヴ・マーセル・ポール バンフォイ、ジーン; ー ヘンチョズ、シビル ルコーネット |
| (57)【要約】 ＣＤ２１，ＣＤ１１ｂ，ＣＤ１１ｃに結合し、内皮細胞上で発現される７０〜８５ＫＤａ蛋白に結合し，または内皮細胞上に発現される１１５ＫＤａ蛋白に結合する結合性物質は、炎症、自己免疫疾患、アレルギー疾患の治療および予防に有用である。 | ||||||
| 142 | Factors affecting the thrombosis hemostasis | JP50348396 | 1995-06-28 | JPH10502351A | 1998-03-03 | デイビッド エル． ウォルフ，; ウマ シンハ， |
| (57)【要約】 一時的に不活性な血液因子のアナログは、血栓症によって特徴づけられる疾患の治療に有用である。 さらに、血清中で活性血液因子を生じるが、延長された半減期を有する活性化血液因子の修飾型は、血友病症状を治療するのに有用である。 血液因子のこれらの修飾型は、インビボにおいてゆっくりと脱アシル化される、アシル化型であり得る。 | ||||||
| 143 | Medical preparation for treatment of blood coagulation disease | JP10801397 | 1997-03-21 | JPH1045620A | 1998-02-17 | TURECEK PETER; SCHWARZ HANS-PETER; EIBL JOHANN |
| PROBLEM TO BE SOLVED: To obtain the subject preparation capable of simple administration, effective start of the action, increasing half life and preventing adverse reaction of agglomeration by including specific components which are clotting factors. SOLUTION: The preparation contains at least two clotting factors which are the components of prothrombinase or pro-prothrombinase, not containing phospholipid. The preparation contains at least one of the factors activated, has at least two clotting factors selected from factors II, V, Va, X and Xa, practically factors II and X or Xa (capable of accompanying V or Va freely), the factor exists as a conjugate, preferably containing magnesium ion but free from free calcium ion. | ||||||
| 144 | Binding substance to the Cd23 | JP51350896 | 1995-10-20 | JPH09511757A | 1997-11-25 | − イヴ・マーセル・ポール バンフォイ、ジーン |
| (57)【要約】 炎症疾患、自己免疫疾患またはアレルギー疾患の治療に有益な、ＣＤ２３に対する結合物質。 | ||||||
| 145 | X factor -laci hybrid protein | JP725691 | 1991-01-24 | JP2560150B2 | 1996-12-04 | TOOMASU JEEMUSU JIRAADO; JOOJI JON BUROZU JUNIA |
| A single-chain hybrid blood coagulation inhibitor is disclosed which has an amino acid sequence composed of two subsequences corresponding to the light chain of Factor X and LACI's first Kunitz domain. |
||||||
| 146 | Stable preparation for treatment of blood coagulation disorder comprising activated coagulation factor and lipid vesicle | JP10945395 | 1995-05-08 | JPH0840928A | 1996-02-13 | YOHAN AIBURU; HANSU PEETAA SHIYUBUARUTSU; YURUGEN JIIKUMAN; PEETAA TOURECHIETSUKU |
| PURPOSE: To provide a stable preparation for the prophylactics and treatment of blood coagulation disorder comprising an activated coagulation factor and, when desired, another protein. CONSTITUTION: This stable preparation for the treatment of blood coagulation disorders comprises an active coagulation promoting substance, such as an activated coagulation factor, and optionally other proteins which are bound in or on lipid vesicles. The activated coagulation promoting substance is an activated coagulation factor, preferably vitamin K-dependent protein, selected from factors IIa, VIIa, IXa and Xa, factor Xaβ is particularly preferred. This composition may contain a protein, in addition, selected from factor II, factor VII, factor IX, factor X, protein C, activated protein C, protein S, and protein Z, and may contain factor VIII, activated factor VIII and/or von Willebrand factor or factor V and/or activated factor V. The lipid vesicle has sizes in the range of 30-900 nm, preferably 100-500 nm according to animal light- scattering method. | ||||||
| 147 | Stable preparation for treatment of blood coagulation disorder | JP10945895 | 1995-05-08 | JPH07304658A | 1995-11-21 | EIBL JOHANN; SCHWARZ HANS PETER; SIEKMANN JUERGEN; TURECEK PETER |
| PURPOSE: To obtain the subject preparation, containing a protein lipid complex in a vesicular form, subjected to a treatment for the inactivation of potentially present viruses and useful for treating blood coagulation disorders containing a coagulation active protein. CONSTITUTION: This stable virally safe preparation contains a protein bound in and/or on lipid vesicles (preferably a coagulation active protein) and is subjected to a treatment for inactivation of potentially present viruses (preferably heat treatment). The preparation preferably contains a blood coagulation factor of an endogenous or an exogenous blood coagulation, preferably an active type blood coagulation factor (e.g. a vitamin K-dependent protein, IIa factor or VIIa factor). The preparation is useful for intravenous injection. COPYRIGHT: (C)1995,JPO | ||||||
| 148 | Virus-inactivated factor xa preparation | JP18132894 | 1994-08-02 | JPH0775572A | 1995-03-20 | TURECEK PETER; EIBL JOHANN; SCHWARZ HANS-PETER |
| PURPOSE: To obtain the subject high-purity, stable Factor Xa preparation having a coagulation Factor Xa activity of specific units per unit weight of protein, and highly suitable for e.g. the treatment of Factor VIII-hemophilia A inhibited patients, from virus-inactivated plasma. CONSTITUTION: This Faxtor Xa preparation is obtained by the following procedures: using, as a starting material, a lyophilized product of prothrombin complex factor preparation containing Factor II, Factor IX, Factor X, protein C and protein S or the like each fractionated from human plasma by a conventional means, then the starting material is heat-treated at 50-90°C to inactivate viruses, dissolved in distilled water, adjusted to pH 7.0, and subjected to chromatography to purify the Factor X. Subsequently, the Factor X-contg. fraction is activated using Vipera russellii venom, a trypsin-like activity-bearing protease or an activated coagulation factor such as Factor VIIa with a cofactor, or a tissue factor until at least 100 units coagulation factor activity per mg protein is afforded. COPYRIGHT: (C)1995,JPO | ||||||
| 149 | JPH06511018A - | JP50358194 | 1993-07-13 | JPH06511018A | 1994-12-08 | |
| 150 | Novel polypeptide | JP25261487 | 1987-10-08 | JPS63159396A | 1988-07-02 | AASAA EMU FUERITSUKUSU; EDOGAA PII HAIMAA; PEETAA PII NAFUROTO; DEBITSUDO EMU SUTAAN; JIYOOJI DEI UIRUNAA |
| 151 | COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE | US16157194 | 2018-10-11 | US20190231856A1 | 2019-08-01 | Steven Arkin; Marcus Carr; Joachim Fruebis; Sunita Hett; Reema Jasuja; Debra Pittman |
| The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa. | ||||||
| 152 | Compositions and Methods for Modulating Hemostasis | US15899609 | 2018-02-20 | US20180251745A1 | 2018-09-06 | Rodney M. Camire |
| Factor Xa variants and methods of use thereof are disclosed. | ||||||
| 153 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | US15833520 | 2017-12-06 | US20180236049A1 | 2018-08-23 | Uma Sinha; Genmin Lu; Athiwat Hutchaleelaha; Stanley J. Hollenbach |
| The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | ||||||
| 154 | Factor X activation | US14824870 | 2015-08-12 | US10036002B2 | 2018-07-31 | Meinhard Hasslacher; Thomas Gatternig; Christian Fiedler; Ernst Böhm; Michael Dockal; Franziska Horling |
| Methods and systems for activating Factor X are disclosed. | ||||||
| 155 | Production of fully processed and functional factor X in a furin-secreting mammalian expression system | US14824927 | 2015-08-12 | US09873892B2 | 2018-01-23 | Ernst Böhm; Franziska Horling; Jadranka Koehn; Michael Dockal |
| Disclosed herein are methods for production of fully-processed mature Factor X in an expression system producing a controlled amount of furin between 50 U/mL and 300 U/mL of culture supernatant. Also disclosed are transformed cells, expression systems, and expression vectors for the expression of furin and Factor X. | ||||||
| 156 | Method for purifying active GLA-domain coagulation proteins | US14936896 | 2015-11-10 | US09850477B2 | 2017-12-26 | Gerard Perret; Nicolas Bihoreau; Laurent Siret |
| The invention relates to a method for purifying biologically active GLA-domain coagulation proteins, comprising the following steps: a) bringing a sample that contains one or more GLA-domain coagulation proteins and may contain biologically inactive molecules of GLA-domain protein(s), into contact with an affinity support on which nucleic aptamers that bind specifically to at least one biologically active GLA-domain coagulation protein are immobilized, in order to form complexes between (i) said nucleic aptamers and (ii) said GLA-domain coagulation protein(s), b) releasing the GLA-domain coagulation protein(s) from the complexes formed in step a), and c) recovering said biologically active GLA-domain coagulation protein(s) in a purified form. | ||||||
| 157 | One component fibrin glue comprising zymogens | US14560089 | 2014-12-04 | US09814765B2 | 2017-11-14 | Yair Pilpel; Ashley Deanglis; Yuri Zherdev; Sivan Doron; Anne Gorman; Israel Nur |
| Provided herein is a single component sealant formulation (e.g. in a liquid form), methods for its preparation, and use. The formulation includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX). | ||||||
| 158 | METHOD OF MANUFACTURING PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION III AND NON-PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION IV | US15286656 | 2016-10-06 | US20170232079A1 | 2017-08-17 | Kieu Hoang |
| The present subject matter is directed to a method of manufacturing and purifying an intravenous injection of prothrombin complex concentration (PCC) from plasma Fraction III and a method of manufacturing and purifying an intravenous injection of non-PCC from plasma Fraction IV. The intravenous injection of PCC and non-PCC obtained from the method can be administered to a patient in need thereof for stopping replication, killing and preventing HIV-1 and HIV-2 in a patient. | ||||||
| 159 | C-terminally tethered amino acids and their fibrinolytic therapeutic uses | US14303101 | 2014-06-12 | US09579367B2 | 2017-02-28 | Ed Pryzdial |
| The present disclosure provides a C-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the C-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins. | ||||||
| 160 | Non-cytotoxic protein conjugates | US14300746 | 2014-06-10 | US09474807B2 | 2016-10-25 | Keith Foster; John Chaddock; Charles Penn; Kei Roger Aoki; Joseph Francis; Lance Steward |
| The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. | ||||||
QQ群二维码
意见反馈
意见反馈